- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulation of rimegepant.
Acute treatment of migraine attacks with or without aura
Migraine in adults: prophylaxis
Acute treatment of migraine with or without aura in adults.
Prevention of episodic migraine in adults who experience 4 or more migraine attacks per month.
Acute treatment of migraine
75mg once daily, as needed.
Prevention of migraine
75mg every other day. Maximum daily dose is 75mg.
Additional Dosage Information
Avoid a second/additional dose of rimegepant within 48 hours of moderate CYP3A4 inhibitors and strong P-gp inhibitors. Avoid taking rimegepant within 2 weeks of discontinuing CYP3A4 inducers.
Children under 18 years
Renal impairment - creatinine clearance below 15ml/minute
Severe hepatic impairment - Child-Pugh score greater than or equal to 10
Precautions and Warnings
Severe renal impairment
Avoid second dose within 48 hours of moderate CYP3A4/strong P-gp inhibitors
Discontinue if hypersensitivity reactions occur
Advise patient not to take St John's wort concurrently
Advise patient to avoid grapefruit products
In the event of frequent or daily headaches, medication overuse headache should be suspected and treatment should be discontinued.
Pregnancy and Lactation
Rimegepant is contraindicated during pregnancy.
Use of rimegepant during pregnancy is contraindicated by the manufacturer. At the time of writing, there is limited published information regarding the use of rimegepant during pregnancy. Potential risks are unknown.
Use rimegepant with caution during breastfeeding.
The manufacturer advises caution if rimegepant is used when breastfeeding. Whilst available data indicates rimegepant is present in human breast milk, the quantity is not considered to be sufficient to cause adverse effects in the breastfed infant. Effects on exposed infants are unknown.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: September 2022
Summary of Product Characteristics: Vydura 75mg oral lyophilisate. Pfizer Ltd. Revised July 2022.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.